Validation of serum paraoxonase/arylesterase 1 (PON1) as a protein marker of illicit dexamethasone treatment in veal calves

被引:1
|
作者
Guglielmetti, Chiara [1 ]
Brusadore, Sonia [1 ]
Pezzolato, Marzia [1 ]
Baioni, Elisa [1 ]
Ingravalle, Francesco [1 ]
Acutis, Pier Luigi [1 ]
Mazza, Maria [1 ]
Bozzetta, Elena [1 ]
机构
[1] Ist Zooprofilatt Sperimentale Piemonte Liguria &, Turin, Italy
关键词
Dexamethasone; veal calves; anabolic treatments; paraoxonase; PON1; 2D electrophoresis; marker; PLASMA-PROTEIN; BIOMARKER; CATTLE; URINE; ABUSE;
D O I
10.1080/19440049.2022.2062057
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The illicit use of dexamethasone and other glucocorticoids for cattle fattening in livestock production has been widely described; evidence for illegal treatments can be obtained by direct or indirect detection. In our previous study, we applied two-dimensional electrophoresis (2DE) to identify plasma protein markers of dexamethasone administration in veal calves. Comparison of 2DE maps obtained from blood samples before and after treatment showed the disappearance of two protein spots identified as serum paraoxonase/arylesterase 1 precursor (PON1). In the present study, we validated PON1 as a marker by analysing a larger number of samples treated with dexamethasone for illicit use. Analysis of samples from experimental treatment with other glucocorticoids, androgens and oestrogens confirmed that their influence on PON1 could be excluded. The specificity of the PON1 protein marker was verified on expected negative field samples to exclude interfering factors. However, there is poor statistical evidence to support a significant association between the outcome of PON1 and the considered variables. The results on field samples were compared with histological examination of the thymus as a biomarker of corticosteroid treatment monitored in the Italian histological plan for the control of growth promoters in animals. Two suspect cases were identified from two Piedmont farms where other animals had tested positive at histological examination. In conclusion, the absence of PON1 in the plasma of veal calves can indirectly reveal illicit dexamethasone treatment in individual animals and so identify suspect farms for further investigation. It is effective in a period ranging from 3 to about 10 days from illicit treatment, covering a time span that goes beyond the limits of official chemical controls and preceding histological controls on the thymus of slaughtered animals. PON1 detection in plasma can be coupled with other tests to identify illegal dexamethasone use on veal calf farms.
引用
收藏
页码:1065 / 1073
页数:9
相关论文
共 50 条
  • [21] Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
    Leviev, I
    James, RW
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) : 516 - 521
  • [22] Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence
    Bard, Jean-Marie
    Jaffre, Isabelle
    Joalland, Marie-Pierre
    Classe, Jean-Marc
    Campone, Mario
    Bobin-Dubigeon, Christine
    FASEB JOURNAL, 2012, 26
  • [23] Further characterization of human serum paraoxonase (PON1) lactonase activity
    Billecke, S
    Draganov, D
    Counsell, R
    Stetson, P
    Watson, C
    Hsu, C
    La Du, BN
    FASEB JOURNAL, 2000, 14 (08): : A1323 - A1323
  • [24] Naringenin is an inhibitor of human serum paraoxonase (PON1): An in vitro study
    Mahrooz, Abdolkarim
    Rashidi, Mohammad-Reza
    Nouri, Mohammad
    CLINICAL BIOCHEMISTRY, 2011, 44 (13) : S249 - S249
  • [25] Naringenin is An Inhibitor of Human Serum Paraoxonase (PON1): An In Vitro Study
    Mahrooz, Abdolkarim
    Rashidi, Mohammad-Reza
    Nouri, Mohammad
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2011, 25 (06) : 395 - 401
  • [26] SERUM PARAOXONASE 1 ARYLESTERASE ACTIVITY AS AN ANTIOXIDANT MARKER IN DIALYSIS PATIENTS
    Korol, Lesya
    Stepanova, Natalia
    Vasylchenko, Victoria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1911 - 1911
  • [27] Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3
    Teiber, JF
    Draganov, DI
    La Du, BN
    BIOCHEMICAL PHARMACOLOGY, 2003, 66 (06) : 887 - 896
  • [28] SERUM PARAOXONASE ACTIVITY AND PON1 192 AND PON1 55 POLYMORPHISMS IN PREPUBERAL CHILDREN. THE FOUR PROVINCES STUDY
    Garces, Carmen
    Lopez-Simon, Laura
    Rubio, Rafael
    Benavente, Mercedes
    Cano, Beatriz
    Viturro, Enrique
    de Oya, Manuel
    del Barrio, J. L.
    de Oya, I.
    Lasuncion, M. A.
    Ortega, H.
    Martin Moreno, J. M.
    Gorgojo, L.
    Royo, M. A.
    Gil, A.
    Rodriguez Artalejo, F.
    Fernandez, O.
    Mangas, A.
    Macias, A.
    Fernandez Pardo, J.
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2007, 19 (06): : 287 - 292
  • [29] Paraoxonase (Pon1) Q192R polymorphism and serum Pon1 activity in diabetic patients on maintenance hemodialysis
    Zhang, B
    Eto, S
    Fan, P
    Bian, C
    Shimoji, E
    Saito, T
    Saku, K
    CLINICAL NEPHROLOGY, 2003, 60 (04) : 257 - 265
  • [30] Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes
    Li, Wan-Fen
    Pan, Mei-Hung
    Chung, Meng-Chu
    Ho, Chi-Kung
    Chuang, Hung-Yi
    ENVIRONMENTAL HEALTH PERSPECTIVES, 2006, 114 (08) : 1233 - 1236